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SINTESIS, STRUKTUR DAN KAJIAN IN VITRO ANTIKANSER
KOMPLEKS DINUKLEAR ARGENTUM N-HETEROSIKLIK KARBENA
DIPEROLEHI DARI KAITAN XYLYL GARAM BIS-BENZIMIDAZOLIUM
ABSTRAK
Kajian ini menerangkan tentang sintesis tiga siri garam bis-benzimidazolium
sebagai prekusor N-heterosiklik karbena (NHC) dan kompleks mereka dengan ion
argentum(I) untuk mendapatkan komplek argentum(I)-NHC. Setiap siri garam adalah
terbitan samada daripada para-, meta-, atau orto-xilin sistem berangkai yang
mempunyai gantian etil-desil, benzil dan i-propil di kedudukan 3 pada cincin
benzimidazolium. Kesemua garam dan kompleks telah dicirikan oleh spektroskopi
(FT-IR, 1H and 13C NMR), analisis unsur (CHN) dan teknik pembelauan sinar-X
kristal tunggal. Semua kompleks telah disediakan melalui tindakbalas in situ diantara
Ag2O dengan garam bis-benzimidazolium yang sepadan dan telah diuji dengan sel
kanser kolon manusia. Bagaimana pun hanya garam dan kompleks terpilih telah diuji
selanjutnya dengan promielositik akut leukemia dan sel leukemia mielogenus abadi.
Garam dan kompleks ini menunjukkan potensi aktiviti antikanser menentang
kesemua sel kanser yang diuji. Walaubagaimana pun, kompleks terbukti mempunya
sitotoksiksiti lebih tinggi berbanding dengan garamnya. Selanjutnya, aktiviti anti-
radang bagi N-heksil gantian para-xylyl berangkai garam bis-benzimidazolium dan
kompleksnya telah diuji. Memandangkan kanser dan keradangan adalah berkait
antara satu sama lain, maka kita mencadangkan bahawa dadah yang mempunyai
potensi antikanser mungkin juga mempunyai potensi terhadap anti-radang.
Menariknya, kedua-dua sebatian ini terbukti mempunyai aktiviti anti-radang. Selain
itu, tindakan mekanisma telah diterokai dan didapati sebatian inhibitor
xxv
siklooksigenase-1 dan siklooksigenase-2 serta sitokin (interleukin-1, α-faktor
nekrosis tumor, and nitrik oksida) adalah penghalang. Dalam semua kes didapati
kompleks mempunyai hasil yang lebih baik dan berganda berbanding dengan garam
masing-masing.
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SYNTHESIS, STRUCTURE AND IN VITRO ANTICANCER STUDIES OF
DINUCLEAR SILVER(I)-N-HETEROCYCLIC CARBENE COMPLEXES
DERIVED FROM XYLYL LINKED BIS-BENZIMIDAZOLIUM SALTS
ABSTRACT
The current study was aimed to synthesize three series of bis-
benzimidazolium salts (12-44) as stable N-heterocyclic carbene (NHC) precursors
and their complexation with silver(I) ions in order to obtain dinuclear silver(I)-NHC
complexes (45-77). Each series of salts was derived either from para-, meta-, or
ortho-xylene linked systems having ethyl-decyl, benzyl and i-propyl substituents at
number 3-position of benzimidazolium ring. The salts and complexes were
characterized by spectroscopy (FT-IR, 1H and 13C NMR), elemental analysis (CHN)
and single crystal X-ray diffraction techniques. All the complexes were prepared by
in situ reaction of Ag2O with the corresponding bis-benzimidazolium salts and were
tested against human colon cancer cells. Selected salts (12-14, 18-20, 21) and
respective complexes (45-47, 29-31, 54) were further tested against acute
promyelocytic leukaemia and immortalized myelogenous leukaemia cells. The
compounds showed potential anticancer activity against all the tested cancer cell
lines. Moreover, complexes exhibited higher cytotoxicity compared to respective
salts. The anticancer potential of compounds increased with the increase in chain
length at position 3-nitrogen. Furthermore, considering the triangular relationship
among cancer, inflammation and oxidation, selected compounds were further tested
for possible anti-oxidant and anti-inflammatory activities. The tested compounds did
not show anti-oxidant behaviour however, proved to have anti-inflammatory activity
comparable to the standards used. Additionally, the anti-inflammatory mechanism of
action was explored and the compounds were found cyclooxygenase-1 and
xxvii
cyclooxygenase-2 inhibitors as well as cytokines (interleukin-1, tumor necrosis
factor-α, and nitric oxide) blockers. In all cases the complexes were found to have
many fold better results compared to the respective salts concluding that silver
imparts an important role against cancer and inflammation.
1CHAPTER ONE
INTRODUCTION
1.1 The N-heterocyclic carbenes
N-heterocyclic carbenes (NHCs) are versatile class of ligands which have
various types based on ring size, starting from the carbenes derived from four
membered N-heterocycles and extend upto seven membered N-heterocycles (Figure
1.1) (Hahn and Jahnke, 2008), among which perhaps five membered NHCs are the
most widely studied carbenes (Bates et al., 2009).
Figure 1.1: Types of NHCs based on ring size with year of discovery. Orbital view of
electron pair in a sp2-hybridized carbon with vacant p-orbital and π-donor N-atoms.
In these carbenes a divalent carbon moiety is flanked by two π-donor nitrogen
atoms. The strong σ-donating and week π-accepting properties of NHCs have
2rendered them as excellent ligands not only for d-block elements (Arnold and
Pearson, 2007) but also for f-block elements (Arnold and Casely, 2009a; Arnold and
Casely, 2009b; Evans, 2007; Evans et al., 1981).
1.2.1 Discovery of NHCs (Background)
Discussion about NHCs was initiated by Wanzlick in 1960 by his report on
the α-elimination of chloroform from I to get free NHC II (Wanzlick and Schikora,
1960). However, Wanzlick could never isolate II and always obtained its dimer II=II
(Hahn and Jahnke, 2008) (Figure 1.2). Wanzlick also tried the cleavage of dimeric
entatraamine according to II=II → 2 × IV using cross-metathesis method but failed
(Lemal et al., 1964; Winberg et al., 1965).
..
Figure 1.2: Formation of dimeric entatraamine II=II instead of free NHC II.
Around 1970, Wanzlick decided to change the starting material for the
generation of free NHC. He tried to prepare the free carbene IV by deprotonation of
1,3,4,5-tetraphenylimidazolium perchlorate III with KOtBu (Schönherr and
Wanzlick, 1970) (Figure 1.3), because at that time it was already known that azolium
cations react in presence of base-catalyzed medium (Fild et al., 1964; Olofson et al.,
1964; Staab et al., 1964). The free carbene again could not be isolated. However,
generation of free NHC IV by this method was detected as the intermediate product
3from the identification of some of its reaction products with water or mercuric acetate
(Schönherr and Wanzlick, 1970).
Figure 1.3: Attempt to synthesize free carbene IV from azolium salt III.
Up to this point, a concept had already developed that a NHC can be
synthesized but only as an intermediate and can’t be isolated as a stable product for
further laboratory or commercial use. However, Arduengo believed that the
intermediate carbene must not be as unstable as was being assumed by scientific
community (Arduengo and Krafczyk, 1998). Finally in 1991, Arduengo and co-
workers synthesized and isolated the first crystallographically elucidated NHC VI
from an azolium salt V in presence of sodium hydride and catalytic amount of DMSO
using THF as reaction medium (Figure 1.4) (Arduengo et al., 1991). This carbene
was found to have a unique stability at room temperature in the absence of oxygen
and moisture. Later on, in 1998 Arduengo et al., also prepared, isolated, and
crystallographically characterized carbene IV (Figure 1.3) that Wanzlick could not
isolate in 1968 (Arduengo III et al., 1998).
4Figure 1.4: Arduengo’s first stable N-heterocyclic carbene VI.
The discovery of first stable carbene VI led to significant interest in the field
of carbene chemistry. To date, different methods for the syntheses of NHCs have
been reported, which include the desulfuration of imidazole-2(3H)-thiones (Kuhn and
Kratz, 1993) and methanol elimination by thermolysis of 5-methoxy-1,3,4-triphenyl-
4,5-dihydro-1H-1,2,4-triazoles (Figure 1.5) (Enders et al., 1995; Hahn and Jahnke,
2008).
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Figure 1.5: The reported methodologies for syntheses of the free NHCs.
51.2.2 The stability of NHCs
Initially, many researchers thought that the unique stability of the NHC,
synthesized by Arduengo, was due to the bulky N-adamantyl substituents which
prevent the dimerisation of the carbene due to steric hindrance. However, Arduengo’s
syntheses of another stable carbene with N-methyl substituents proved otherwise
(Arduengo et al., 1992). Arduengo justified that the electronic contributions are the
main stabilizing factors which involve electron donation from the adjacent nitrogen
atoms to the vacant p(π) orbital of the carbene carbon (Figure 1.6).
Lone pair
for coordinaion
Vacant p-orbital
e- donation
(resonance)
e- withdrawal
(Inductive effect)
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N
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Figure 1.6: Orbital (a) and resonance (b) representations of electronic stabilization in
imidazole-2-ylidenes.
Hence the role of N-substituents is unique, for example the π-donor
substituents increase pπ character of the singlet carbene (see Figure 1.7) by
transferring π electrons to the empty p-orbitals of the carbene carbon (Bourissou et
al., 1999) and consequently, the bulky substituents on the nitrogen atoms contribute
to the stability of the carbenes (Bourissou et al., 1999; Hahn et al., 2000).
Furthermore, due to higher electronegativity of nitrogen as compare to carbon atom,
6charge density is considered to be inductively withdrawn through the σ-framework,
stabilizing the carbene lone pair (Arduengo et al., 1992).
Figure 1.7: The orbital representation of singlet and triplet carbenes. In singlet
carbenes unshared electrons are present in the same orbital whereas in triplet carbenes
these electrons are present in two different orbitals.
1.3 Syntheses of azolium salts: the NHC precursors
Azolium salts are generally synthesized by two common synthetic routes
(Weskamp et al., 2000):
1.3.1 Nucleophilic substitution starting at the azole heterocycle.
In this route, azole (imidazole, benzimidazole, triazole etc) heterocycle is first
reacted with a strong base (eg., KOH, NaOH) to get potassium or sodium azolide that
is subsequently reacted with one equivalent of alkyl or aryl halide in appropriate
solvent to collect the 1-alkyl or 1-aryl azole (Herrmann, 2002; Starikova et al.,
2003b). 1-substituted azole is then reacted with one equivalent of alkyl or aryl halide
of interest at position 3-nitrogen (Figure 1.8). This method allows the syntheses of
unsymmetrical imidazolium salts by stepwise alkylation.
7Figure 1.8: General representation of syntheses of benzimidazolium salts by
neucleophilic substitution.
1.3.2 Multi-components reaction, building up the heterocycle with the appropriate
substituents in one step.
In this route, primary amines, glyoxal, and formaldehyde are reacted in the
presence of Brǿnsted acid as one pot reaction (Figure 1.9) (Böhm et al., 2000;
Herrmann et al., 1996).
Figure 1.9: General representation of syntheses of imidazolium salts by multi-
components reaction.
This flexible route is suitable for the syntheses of symmetrical 1,3-substituted
azolium salts. However, unsymmetrical substituted azolium salts can also be
synthesized by combining a multicomponent cyclization with N-alkylation reaction
(Gridnev and Mihaltseva, 1994). According to this method, an initial cyclization at
pH 1 yields an N-alkylazolium salt that is subsequently alkylated at second nitrogen
atom in presence of base to give the asymmetrically substituted derivative
(Figure 1.10).
8Figure 1.10: General representation of multicomponent cyclization and N-alkylation.
The 1,3-alkyl/aryl-substitutions facilitate the lone pairs at nitrogen atoms to
resonate on NCN framework. This phenomenon makes position 2-hydrogen acidic to
be easily removed by a suitable base (Figure 1.10). In the current study, syntheses of
bis-benzimidazolium salts were carried out according to the route 1.3.1 (page 6) with
minor modifications.
1.4 Syntheses of NHC complexes (Discovery of M-NHC complexes)
Although, the first stable N-heterocyclic carbene was only isolated in 1991, its
complexation with metals (Cr and Hg) was already achieved 22 years earlier by Öfele
and Wanzlick (Öfele, 1968; Wanzlick and Schönherr, 1968) independently.
Öfele and co-workers were actually trying to synthesize some dihydro
complexes by heating the hydropentacarbonyl chromium heterocyclic salt. They
found that there is an unusual reaction when imidazolium salts used, which lead to
the formation of an N-heterocyclic carbene chromium complex shown in Figure 1.11.
Figure 1.11: Öfele’s chromium-NHC complex.
9At the same time, Wanzlick and Schönherr synthesized a mercury(II)-NHC
complex by a direct reaction between 1,3-diphenylimidazolium perchlorate and
mercury(II) acetate (Figure 1.12) in DMSO. In this reaction, the acetate ions play the
main role that is the in situ deprotonation of the imidazolium salt and release of the
acetic acid to form the complex. Later on, the metal acetate route was adopted as one
of the general routes for the syntheses of several transition metal-NHC complexes.
Figure 1.12: Wanzlick’s mercury(II)-NHC complex.
Since the discovery of Öfele’s Cr(III)-NHC and Wanzlick’s Hg(II)-NHC
complexes that , NHCs have been widely synthesized and used in organometallic and
inorganic chemistry. The first comprehensive review about the synthetic methods of
free NHCs and their coordination chemistry was compiled by Herrmann and Köcher
about 15 years ago (Herrmann and Köcher, 1997) and the latest one by Hahn and
Jahnke about 5 years ago (Hahn and Jahnke, 2008) which additionally describes the
types of NHCs. Catalytic applications of this class have been reviewed by Herrmann
(Herrmann, 2002), Crudden (Crudden and Allen, 2004), and Glorius (Glorius, 2007)
whereas biological applications by K-Nebioglu (Kascatan-Nebioglu et al., 2007),
Garrison (Garrison and Youngs, 2005), and recently by Teyssot (Teyssot et al.,
2009a). Several methods have been explored for the preparation of NHC complexes
(Enders and Gielen, 2001; Peris and Crabtree, 2003; Weskamp et al., 2000). To date,
NHCs have been incorporated to almost all the transition metals of periodic table
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using different synthetic routes (Arnold and Pearson, 2007; Evans, 2007). A brief
review by Weskamp describes various synthetic routes for bonding transition metals
to NHCs (Weskamp et al., 2000).
1.5 Syntheses of silver(I)-NHC complexes
Syntheses of silver(I)-NHC complexes have been reported mainly by four
routes: (1.5.1) generation of free carbene from azolium salt and subsequent reaction
with a silver salt, (Arduengo et al., 1993; Caballero et al., 2001a; Chung, 2002; Fox et
al., 2002), (1.5.2) In situ reaction of azolium salts with basic silver reagents, (Arnold,
2002; Chianese et al., 2004; Danopoulos et al., 2003; Guerret et al., 2000; Guerret et
al., 1997; Herrmann et al., 2004; Hu et al., 2004; Mayr et al., 2004; Melaiye et al.,
2005; Tulloch et al., 2000; Wanniarachchi et al., 2004), (1.5.3) in situ reaction of
azolium salts with a base in presence of silver salt, (Wang and Lin, 1998), (1.5.4)
transmetallation from a tungsten NHC to silver (Ku et al., 1999).
1.5.1 Free carbene route
The first silver(I) N-heterocyclic carbene complex was synthesized by this
route in 1993 (Figure 1.13) (Arduengo et al., 1993). According to this method,
deprotonation of azolium salts was accomplished by a strong base (like KH or
KOtBu) and free NHC was subsequently reacted with the silver source. Following
Arduengo, several silver(I)-NHC complexes have been reported using this method
(Caballero et al., 2001a; Caballero et al., 2001b; Chung, 2002; Fox et al., 2002).
Currently, this method is not popular due to strict reaction conditions and
decomposition of some specific azolium salts (Caballero et al., 2001a; Caballero et
11
al., 2001b; César et al., 2002; Chen et al., 2002; Guerret et al., 2000; McGuinness and
Cavell, 2000; Wang et al., 2004).
Figure 1.13: Syntheses of first silver N-heterocyclic carbene complex (1993).
1.5.2 Base in the presence of a silver salt
This method was first reported by Wang and Lin in 1998 (Wang and Lin,
1998). These researchers used a basic phase transfer catalyst to synthesize VII from
benzimidazolium bromide in presence of AgBr (Figure 1.14). However, this
procedure was proved unsuccessful for other imidazolium salts (Tulloch et al., 2000).
N
N
Br-
AgBr
Bu4N+Br-, NaOH N
N
N
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Figure 1.14: Wang and Lin’s method of base in presence of silver salt.
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1.5.3 Transmetallation to silver(I)-NHC complexes
This method was proposed by Liu and co-workers in 1998 (Liu et al., 1998).
However, transmetallation from tungsten(0) N-heterocyclic carbene complexes to
silver was achieved in 1999 (Ku et al., 1999; Liu and Reddy, 1999). Although the
claimed compounds could neither be isolated nor structurally characterized, however
spectroscopic evidences indicated the successful transformations. This method was
largely abandoned because silver NHC complexes generated from this method were
found to be sensitive to moisture, which is not the characteristic of silver NHC
complexes. Later on, transmetallation from other metal centers (Mo(0), Cr(0), Rh(I),
Pd(II), Pt(II)) was suggested but sufficient spectroscopic or structural evidences
couldn’t be generated to substantiate this assertion (Chen et al., 2001; Liu and Reddy,
1999).
Figure 1.15: Transmetallation from tungsten(0) NHC to Ag and dissociation of silver
complexes.
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1.5.4 “Silver Base” route
This is the most widely used method for the syntheses of silver-NHC
complexes. In this method deprotonation and coordination phenomenon occurs
spontaneously in a single step.
This method was first reported by Wang and Lin in 1998 using Ag2O
(Figure 1.16) (Wang and Lin, 1998). A detailed mechanism for these reactions has
been described by Hayes and co-workers (Hayes et al., 2007).
Figure 1.16: Syntheses of silver N-heterocyclic carbene complexes using silver oxide.
Other silver bases such as AgOAc and Ag2CO3 have also been reported
successfully (Figure 1.17). For example, the use of AgOAc was first introduced by
Bertrand and colleagues by reporting the first silver NHC polymer (Scheme 1.15a)
(Guerret et al., 2000; Guerret et al., 1997). Tulloch et al., reported a series of silver
NHC complexes of structure shown in Scheme 1.15b by using Ag2CO3 as metallation
agent (Tulloch et al., 2000). The use of Ag2CO3 was also successfully employed by
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others (Van Veldhuizen et al., 2002). However, reaction durations using this reagent
were reported to be longer than reaction times using Ag2O (Tulloch et al., 2000).
(a)
(b)
Figure 1.17: (a) Syntheses of silver-NHC polymer using AgOAc and (b) Syntheses of
bridging complexes using Ag2CO3.
Literature shows that in this route the most frequently used “metal base” is
silver oxide (Baker et al., 2005; Bonnet et al., 2003; Catalano et al., 2004; Chianese et
al., 2004; Chiu et al., 2005; De Frémont et al., 2005; Frøseth et al., 2005; Herrmann et
al., 2004; Hu et al., 2004; Lee et al., 2004; Liu et al., 2003; Mata et al., 2004; Mayr et
al., 2004; Melaiye et al., 2004; Quezada et al., 2004; Ramírez et al., 2005; Ramnial et
al., 2003; Sentman et al., 2005; Simons et al., 2003; Tulloch et al., 2000; Wang and
Lin, 1998; Wanniarachchi et al., 2004) because the reactions can be easily monitored
by the uptake of unreacted silver oxide and found to be faster than using other bases.
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The reactions of silver oxide with azolium salts have been carried out successfully in
solvents, such as dichloromethane, 1,2-dichloromethane, DMSO, acetone, methanol,
acetonitrile, DMF, and water. Hence, in present study “Silver Base” route was
adopted with minor modifications.
1.6 Applications of silver(I)-NHC complexes
1.6.1 Ligand transfer chemistry
Many NHC complexes are synthesized directly from the azolium salts by
deprotonation and subsequently reacting with the desired metals. However, many
ligands fail to metalate directly. Many researchers used silver(I)-NHC complexes for
the purpose of transferring metal center to the other metals of interest.
Transmetallation reactions using silver(I)-NHC can be carried out under aerobic
conditions and even in the presence of moisture. To the date, transmetallation using
silver(I)-NHC complexes has been successfully achieved for a variety of metals:
Au(I), Cu(I), Cu(II), Ni(II), Pd(II), Pt(II), Rh(I), Rh(III), Ir(I), Ir(III), Ru(II), Ru(III),
and Ru (IV). The metal to which silver(I)-NHC complexes are most widely
transferred is perhaps palladium, where a variety of Pd reagents have been used for
transmetallation: Pd(cod)Cl2, (César et al., 2002; Danopoulos et al., 2003; Frøseth et
al., 2003; Magill et al., 2001; Tulloch et al., 2003) Pd(cod)Br2, (Tulloch et al., 2003)
Pd(cod)CH3Cl, (McGuinness and Cavell, 2000; Neilson et al., 2012; Tulloch et al.,
2003) PdCl2, (Chiu et al., 2005; Lee et al., 2004; Lee et al., 2005) PdCl2(PhCN)2
(Simons et al., 2003).
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1.6.2 Catalysis
Silver(I)-NHC complexes have also been studied for their catalytic potential.
However, compared to the other M-NHC complexes (M = Pd, Ru, Ni, Ir, Rh)
(Herrmann, 2002) very few studies have been reported for silver(I)-NHC complexes.
Ramirez and co-workers were the first to study the catalytic activity of silver(I)-NHC
complexes (Ramírez et al., 2005). They reported the catalytic use of silver complexes
for diboration reactions with terminal and internal alkenes. Sentman et al., and
Bonnet et al., studied catalytic activity of silver(I)-NHC complexes for ring opening
polymerization of L-lactide (Bonnet et al., 2004; Sentman et al., 2004). This area is
not that widespread for this class of compounds.
1.6.3 Biological
1.6.3.1 Silver a medicinally important metal
Silver is a medicinally valuable metal. Early civilizations used this metal to
purify and store water (Russell and Hugo, 1994). Silver nitrate was frequently used as
antimicrobial long before 18th century and it was well recognized as an antiseptic in
wound care for more than 200 years (Lansdown, 2004). In the 19th century, another
useful medicinal application of silver compounds was explored i.e., at very low
concentrations, silver compounds were found to kill certain microorganisms (Russell
and Hugo, 1994; V. Von Nageli, 1893). In 1881, Créde introduced the use of 1%
silver nitrate solution to prevent the eye infections in newborns (Lansdown, 2004).
The method is still in use today. The use of colloidal silver solutions to avoid the
irritation associated with silver nitrate was introduced in early 20th century (Gibbs,
1999; Lansdown, 2002b). This method remained valid until 1940s. The silver
compounds gradually lost interest following the discovery of penicillin and few other
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new antibiotics (Lansdown, 2004). Then in 1965, the use of 0.5% silver nitrate
solution for the treatment of burn wounds by Moyer (Moyer et al., 1965) re-
established the medicinal interest of silver. Moreover in 1968, the discovery of silver
sulfadiazine was the true revival of silver antibiotics (Fox, 1968).
In the 21st century, organic and inorganic silver compounds have been
introduced in wound dressings (Graham, 2005; Tomaselli, 2006). Silver has been
utilized in several different kinds of wound dressings including nylon fabrics,
meshes, biodegradable colognes, low adherent materials, carbon fibers, and
hydrofiber alginates (Graham, 2005; Lansdown, 2004). These silver containing
dressings have been used in the treatment of acute and chronic wounds, leg ulcers and
several degrees of burn wounds (Graham, 2005).
The pure silver metal is inactive; whereas, in the presence of moisture, silver
readily ionizes to generate silver cations, which then show antimicrobial activity
(Lansdown, 2002a; Lansdown, 2004). Furthermore, the activity of silver cations in
living systems depend on their bioavailability (Silver, 2003) that is further dependent
on delivery methods, solubility, ionization of silver sources and the presence of
biologically compatible ligands (Melaiye et al., 2004; Silver, 2003).
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1.6.3.2 Benzimidazole: a medicinally important heterocyclic moiety
Benzimidazole is an aromatic organic compound, composed of benzene ring
fused with imidazole (Figure 1.18). Its empirical formula and molecular weight is
C7H6N2 and 118.14 g/mol respectively. Benzimidazole is a medicinally important
heterocyclic moiety. For example, N-ribosyl-dimethylbenzimidazole is a naturally
occurring derivative of benzimidazole which serves as an axial ligand for cobalt in
vitamin B12 (Barker et al., 1960). This makes benzimidazole a biologically accepted
pharmacophore in the field of medicinal chemistry as its derivatives are structural
isosters of naturally occurring nucleotides, which makes them compatible with the
biopolymers of the living systems (Narasimhan et al., 2012).
Figure 1.18: Representation of benzimidazole moiety and numbering.
This biological compatibility of benzimidazole has created interest in
researchers to synthesize its organic derivatives and to screen them for biological
activities. To the date, a number of benzimidazole derivatives have been successfully
synthesized and tested as protein kinase CK2 inhibitors (Andrzejewska et al., 2003;
Pagano et al., 2004), tyrosine kinase inhibitors (Zien et al., 2003), and topisomerase
inhibitors (McBride et al., 2006; Pinar et al., 2004). Benzimidazole was also found
active against a wide variety of pathogenic viruses, for example benzimidazoles have
shown good results as antiviral (De Clercq and Naesens, 2006; Starcevic et al., 2007),
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antihepatitic (Ishida et al., 2006; Li et al., 2007), anti-HIV (Middleton et al., 2004),
antienteroviral (Ramla et al., 2007a), anti-RSV (Andries et al., 2003), antibacterial
(Goker et al., 2005; He et al., 2003; Kumar et al., 2002), antifungal (Goker et al.,
2002; Kawasaki et al., 2003), antianthelmintic (Mavrova et al., 2006), antiamoebic
(Lopez-Vallejo et al., 2007; Sondhi et al., 2002), antiprotozoal (Andrzejewska et al.,
2004; Ismail et al., 2004), and antimycobacterial (Klimesova et al., 2002) agents.
Benzimidazoles have also been tested for diabetes (Minoura et al., 2004),
hypertension (Estrada-Soto et al., 2006), inflammation (Mader et al., 2008; Snow et
al., 2007) and allergy (Nakano et al., 2000).
In the last decade, very few benzimidazole derivatives were tested against
cancer. For example, compound VIII, as shown in Figure 1.19, was tested against
MCF-7 (breast cancer), HL-60 (Leukemia), HT-29 (Human colon carcinoma), and
PC-3 (Prostate cancer) whereas IX against HT-29 only (Kumar et al., 2002; Vedula et
al., 2003). Compound X was tested against A-549 (Human lungs carcinoma), BFTC-
905 (Bladder carcinoma), RD (Human embryo rhabdomyosarcoma), MES-SA
(Human sarcoma carcinoma), and HeLa (Cervical cancer) cancer cell lines showed
better results than UK-1 analogues (Huang et al., 2006). Compound XI was tested
against Epstein-Barr virus early antigen (EBV-EA) and was found potentially active
(Ramla et al., 2007b).
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VIII IX
X XI
Figure 1.19: Benzimidazole derivatives tested against various types of cancer.
However, on the basis of literature, it was found that benzimidazolium salts
have never been tested against any type of cancer. This research also fills up this
area of gap.
1.6.3.3 Cancer and metal-based drugs
Cancer is the uncontrolled growth of abnormal cells in a living system that
initially induces tumor (Figure 1.20). If not treated properly, a tumor invades in the
nearby parts of the body and hampers the normal functions of other cells. This
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process continues which leads to a number of ailments and in some cases death. A
detailed introduction of cancer is beyond the scope of this thesis.
Figure 1.20: Diagram showing malignant tumor.
Beside the fact that cancer is curable at initial stages, it has however become
one of the most fatal diseases as the mortality rate due to cancer is increasing
worldwide. According to the global cancer statistic report, in 2002, 10.9 million new
cancer cases were registered all around the world and 6.7 million patients died,
whereas within the next five years (2008) this number increased to 12.6 million new
cases and 7.5 million deaths. A rapid development in anti-cancer drug discovery has
become substantial (Parkin et al., 2005).
Different therapeutic options like chemotherapy, radiotherapy and surgery are
now extensively used to cure different types of cancer. In chemotherapy, the
exploration of cisplatin (Figure 1.21) as an anticancer agent by Rosenberg and co-
workers is perhaps the first historical example of metal-based anticancer drugs
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(Rosenberg et al., 1965; Rosenberg et al., 1967; Rosenberg et al., 1969). However,
the severe side effects (nephrotoxicity, neurotoxicity, and ototoxicity) confined its
applications. In addition, it’s poor solubility in water, chemical incompatibility to
thiols, and natural or developed resistance of some tumours towards cisplatin further
decreased its medicinal worth (Lippert, 1999). However, discovery of cisplatin
provided an opportunity to further explore the metal-based anticancer drugs. Later on,
a number of cisplatin analogous compounds were synthesized and biologically
evaluated but only few of them proved to have pharmacological advantages over
cisplatin and are being used worldwide for tumor therapy (Figure 1.21) (Wheate et
al., 2010).
Figure 1.21:  Worldwide approved platinum-based anticancer drugs.
Platinum based drugs are now so frequently used that only oxaliplatin is
expected to cross 2 billion Euros business in the next two years (Berners-Price,
2011). This drug was recently approved to be used as a second line therapy in
metastatic colorectal cancer and showed minor side affects so far which can be
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treated symptomatically. In addition to platinum, a wide range of transition-metal
drugs have been at various stages of development (Alessio, 2011; Gasser et al., 2011;
Hannon, 2007).
Figure 1.22: Examples of some transition metal complexes having potential
anticancer properties.
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For example (Figure 1.22), two ruthenium based drugs, NAMI-A and KP1019 have
been in preclinical and clinical phase I and II (Hartinger et al., 2008; Rademaker-
Lakhai et al., 2004); two titanium based drugs, Budotitane and Titatocene have also
been reported in phase I and II respectively (Abeysinghe and Harding, 2007); an iron
based drug, Ferrocifen is in its preclinical formulation studies (Vessières et al., 2005);
a gold complex, [Au(dppe)]+ was subjected to preclinical studies in late 1986.
However, none of these could pass all the stages of clinical development until today.
Recently, metal-NHCs appeared as a rapidly growing field of research in
medicinal chemistry. This is also evident from several recent research reports,
reviews and patents (Chardon et al., 2012; Eloy et al., 2012; Gasser and Metzler-
Nolte, 2012; Gautier and Cisnetti, 2012; Haque et al., 2013; Liu and Gust, 2013;
Medvetz et al., 2008a; Monteiro et al., 2012; Oehninger et al., 2013; Teyssot et al.,
2009a; Wang et al., 2011).
1.6.3.4 Silver(I)-NHC complexes as potential anti-cancer metallodrugs
Silver(I)-NHC complexes have been widely tested for their antimicrobial
activities (Kascatan-Nebioglu et al., 2007). However, they were rarely studied for
their anticancer activity (Teyssot et al., 2009a), until recently.
In this regard, Youngs, Tacke and Gautier’s research teams are at the
forefront. Youngs recently reported anticancer properties of a series of Ag(I)-NHC
complexes of structures NHC-Ag-OAc and NHC-Ag-NHC on various cell lines
(Medvetz et al., 2008b; Siciliano et al., 2011). These complexes were found to be
efficient on OVCAR-3 (ovarian cancer) and MB157 (breast cancer) cells whereas no
